Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Amortization of Deferred Charges (2019 - 2025)

Historic Amortization of Deferred Charges for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to $104000.0.

  • Benitec Biopharma's Amortization of Deferred Charges rose 6000.0% to $104000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $330000.0, marking a year-over-year increase of 2890.62%. This contributed to the annual value of $330000.0 for FY2025, which is 2890.62% up from last year.
  • Latest data reveals that Benitec Biopharma reported Amortization of Deferred Charges of $104000.0 as of Q2 2025, which was up 6000.0% from $93000.0 recorded in Q1 2025.
  • Benitec Biopharma's 5-year Amortization of Deferred Charges high stood at $104000.0 for Q2 2025, and its period low was $48000.0 during Q1 2021.
  • Over the past 5 years, Benitec Biopharma's median Amortization of Deferred Charges value was $62000.0 (recorded in 2022), while the average stood at $64111.1.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first soared by 166.67% in 2023, then skyrocketed by 6000.0% in 2025.
  • Quarter analysis of 5 years shows Benitec Biopharma's Amortization of Deferred Charges stood at $58000.0 in 2021, then grew by 5.17% to $61000.0 in 2022, then rose by 3.28% to $63000.0 in 2023, then grew by 6.35% to $67000.0 in 2024, then skyrocketed by 55.22% to $104000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $104000.0 for Q2 2025, versus $93000.0 for Q1 2025 and $67000.0 for Q4 2024.